Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

2.00
-0.0050-0.25%
Volume:315.90K
Turnover:628.25K
Market Cap:87.29M
PE:-3.93
High:2.03
Open:2.01
Low:1.93
Close:2.01
52wk High:4.34
52wk Low:1.53
Shares:43.64M
Float Shares:42.34M
Volume Ratio:0.97
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5092
EPS(LYR):-0.6115
ROE:-268.30%
ROA:-95.51%
PB:7.73
PE(LYR):-3.27

Loading ...

Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged

TIPRANKS
·
Jul 03

Analysts’ Opinions Are Mixed on These Healthcare Stocks: LivaNova (LIVN), Gain Therapeutics (GANX) and Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jul 02

Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained

TIPRANKS
·
Jul 01

Gain Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Jul 01

Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines

Dow Jones
·
Jun 30

Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial

TIPRANKS
·
Jun 30

Gain Therapeutics receives FDA clearance of GT-02287 IND application

TIPRANKS
·
Jun 30

Gain Therapeutics Wins FDA IND Clearance for Parkinson’s Drug Gt-02287 Phase 2 Trial

Reuters
·
Jun 30

Gain Therapeutics - FDA Decision Allows Initiation of Phase 2 for Gt-2287 in Parkinson's Disease

THOMSON REUTERS
·
Jun 30

Gain Therapeutics - Gt-2287 Phase 2 Clinical Development in U.S. Expected to Initiate During 3Q26

THOMSON REUTERS
·
Jun 30

Gain Therapeutics Shareholders Confirm Board and Auditor Choices

TIPRANKS
·
Jun 26

Gain Therapeutics CEO to speak at H.C. Wainwright Neuro Perspectives Summit

Reuters
·
Jun 10

Gain Therapeutics (GANX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Travere Therapeutics (TVTX)

TIPRANKS
·
May 28

Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained

TIPRANKS
·
May 27

Gain Therapeutics presents data from Phase 1b study of GT-02287

TIPRANKS
·
May 26

BRIEF-Gain Therapeutics Says MDS-UPDRS Scores Remain Stable After 150 Days Of GT-2287 Treatment

Reuters
·
May 26

Gain Therapeutics Inc - Mds-Updrs Scores Remain Stable After 150 Days of GT-2,287 Treatment

THOMSON REUTERS
·
May 26

Gain Therapeutics Inc - 4.8 Point Difference in Mds-Updrs Scores at Day 150 Between Glusph Groups

THOMSON REUTERS
·
May 26

Gain Therapeutics reports stable MDS-UPDRS scores at Day 150 in Phase 1b trial of Parkinson’s drug GT-02287

Reuters
·
May 26